September 5, 2017:  Protembis announces successful first-in-human use of its ProtEmbo® Cerebral Protection System in European trial

Protembis announced today the first clinical applications of its ProtEmbo® Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo® System is an intra-aortic filter device that deflects embolic material arising during TAVR away from the brain.

July 28, 2015:  Medical device company Protembis GmbH has closed its seed financing round

Led by Innovationsstarter Fonds Hamburg GmbH, Geratherm Medical AG and a group of angel investors, the financing will fund R&D and clinical trials of its novel cerebral protection device.

CLICK HERE FOR PROGRAM

Come and meet Protembis at PCR Innovators Day London 2017

Click image for program

April 24. 2015:  Protembis wins state subsidy programme

Protembis wins state subsidy programme “KMU-innovativ” for innovative small and medium-sized enterprises granted by Germany's Federal Ministry of Education and Research.

July 25, 2017:  Protembis initiates collaboration with German Accelerator Life Sciences  

Protembis initiates the collaboration with the German Accelerator Life Sciences (GALS) program, an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), to facilitate its U.S. expansion and accelerate its clinical development plans.

CAUTION: The ProtEmbo Cerebral Protection System is approved for investigational use in Europe.    ​​

© 2017 Protembis GmbH, all rights reserved.

Imprint     Privacy